European Pharma Days

April 23 - 24, 2024

Mannheim, Germany

Join us for the European Pharma Days

Join Bruker for the annual European Pharma Meeting taking place on April 23rd - 24th 2024 organized by Bruker, M2Aind and CeMOS – Center for Mass Spectrometry and Optical Spectroscopy.

In this exciting 2-day event we have speakers from the pharmaceutical industry and academia discussing with you their strategies in Drug Targeting Approaches, Biomarker Discovery and Biopharmaceutical Characterization.

Take advantage of the opportunity to find out about the newest insights in the field of Metabolomics, Proteomics, MALDI Imaging and drug discovery. Do not miss the state-of-the-art scientific research presentations by Bruker customers.

The 2-day event is held in a safe, comfortable environment where you can meet and learn from the leading scientist in the pharmaceutical industry and academia. There is plenty of time for networking and discussion during the breaks, where you can engage with our partners in the exhibition area.

Reserve your free seat by clicking the registration link below.

 

Location:

MAFINEX Technologiezentrum
Julius-Hatry-Straße 1
68163 Mannheim


 

Agenda

Day 1: Tuesday, April 23, 2024

10:30 Registration open

11:00 - 11:20 Opening
Prof. Angelika Altmann-Dieses, Ph.D., Director, Mannheim University of Applied Sciences, Mannheim, Germany
Christian Albers, Ph.D., Business Development Manager, Pharmaceutical Markets, DACH/Nordics, Bruker Daltonics, Bremen, Germany

11:20 - 11:45 Top-down mass spectrometry/ion mobility spectrometry for intact protein structure/function studies
Prof. Ole Nørregard Jensen, Ph.D., Department of Biochemistry and Molecular Biology, Biomedical Mass Spectrometry and System Biology, University of Southern Denmark, Odense, Denmark

11:45 - 12:10 A region-resolved proteomic map of the human brain enabled by high-throughput proteomics
Johanna Tüshaus, Ph.D., Chair of Proteomics and Bioanalytics; Postdoc Kuster lab, Technical University of Munich, Freising, Germany

12:10 - 12:35 Multimodal In-depth spatial lipid profiling via vibrational spectroscopy and MALDI Imaging
Lars Gruber, Master of Science, Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim, Germany 

12:35 - 14:05 Lunch Break

14:05 - 14:30 High Throughput Single Cell Metabolomics  
Shawn Owens, Ph.D., Imaging Mass Spectrometrist, SpaceM: A startup out of the BioInnovation Institute and EMBL, Copenhagen, Denmark

14:30 - 14:55 In-depth exploration of on- and off-target effects of PROTACs
Katrin Stavenhagen, Ph.D., Associate Principal Scientist, AstraZeneca, Gothenburg, Sweden 

14:55 - 15:20 Insight into protein interaction and dynamics through HDX-MS  
Petr Man, Ph.D., Senior researcher, Laboratory of structural biology and cell signalling, BioCeV-IMIC, Prague, Czech Republic

15:20 - 16:00 Coffee Break

16:00 - 16:25 Metabolomics in drug discovery  
Karin Meier, Ph.D., Post Doctorate Scientist in Infectious Disease Research, Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., Zurich, Switzerland 

16:25 - 16:50 DEPC based CL-MS: a simple technique to elucidate site-specific structural changes along with disulfide scrambling in monoclonal antibody
Manasi Gaikwad, Ph.D., Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim, Germany

16:50 - 17:30 Roundtable discussion

17:30 - 18:30 Networking

 

Day 2: Wednesday, April 24, 2024

9:00 - 9:25 Advances in spatial mass spectrometry enable in-depth neuropharmacodynamics  
Prof. Per Andren, Ph.D., Platform Scientific Director, Spatial Mass Spectrometry, Science for Life Laboratory, Uppsala University, Uppsala, Sweden

9:25 - 9:50 Unbiased validation of degrader drug targets by high-sensitivity slice-PASEF mediated global ubiquitinomics
Uli Ohmayer, Ph.D., Head of Mass Spectrometry, NEOsphere Biotechnologies, Planegg, Germany

9:50 - 10:15 Ultrasensitive Ligandomics
Otto Kari, Ph.D., Vice President & Head of Antigen Business Unit, ValoTx, Helsinki, Finland  

10:15 - 10:55 Coffee Break

10:55 - 11:20 Multimodal metabolomics of SARS-CoV-2 infection identifies antiviral nucleosides in serum and urine and uncovers an impaired NAD+ pathway and SIRT1 activation
Christoph Trautwein, Ph.D., Core Facility Metabolomics, Medical Faculty University of Tübingen, Germany

11:20 - 11:45 Expanding the MAPPs Assay to survey the MHC-II-DR, -DP and –DQ Receptors for Improved Predictability of Potential T Cell Epitopes
Axel Ducret, Ph.D., Expert Scientist, Pharmaceutical Sciences - Investigative and Immunosafety Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland 

11:45 - 12:10 Mass Spectrometry Imaging integration within spatial biology: A Pharmaceutical perspective
Gregory Hamm, Ph.D., Director Integrated Imaging Sciences, Imaging & Data Analytics, AstraZeneca, Cambridge, UK

12:10 - 13:40 Lunch Break

13:40 - 14:05 Proteomics in Target Discovery
Nico Zinn, Ph.D., Associate Director - Omics Sciences, Cellzome a GSK Company, Heidelberg, Germany

14:05 - 14:30 How to explore small molecules in small samples – a spheroid case study
Stefania Alexandra Iakab, Ph.D., Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim, Germany

14:30 - 14:45 Wrap-Up

 

For Research Use Only. Not for use in clinical diagnostic procedures.